Tocotrienols · Tocotrienols (alpha-, beta-, gamma-, delta- forms of Vitamin E)
A less common form of vitamin E, structurally distinct from standard tocopherols, studied for cholesterol effects (mixed results) and, in preclinical work, for senescence/SASP-suppressing properties.
Short answer
Tocotrienols (Tocotrienols (alpha-, beta-, gamma-, delta- forms of Vitamin E)) is a antioxidant / senolytic potential with evidence grade C, meaning it is backed by mixed or small human trials. We track 0 produkter containing Tocotrienols. The top-ranked product scores 0 out of 10 on our composite scale (dose, evidence, price, testing, transparency). Prices range up to $0.00 per månad.
What it is
Vitamin E exists as eight related molecules — four tocopherols and four tocotrienols. Tocotrienols are found concentrated in palm oil, rice bran oil, and annatto, and have a different, generally more potent antioxidant profile than the common alpha-tocopherol most people know as "vitamin E."
Why people take it
Beyond general antioxidant activity, tocotrienols have shown in preclinical/in vitro work an ability to suppress the senescence-associated secretory phenotype (SASP) — the inflammatory signaling that senescent "zombie" cells put out — positioning them as a candidate senolytic-adjacent compound, though this is far from proven in humans.
Our verdict
Human trial results are inconsistent: an early trial found no lipid benefit, while a more recent trial in chronic kidney disease patients found meaningful LDL/cholesterol/CRP reductions. The proposed senolytic mechanism remains preclinical/in vitro only. This is a supplement with mixed direct human evidence and speculative extrapolation to longevity.
Structure & class
Tocotrienol Rich Fraction (TRF) supplements typically blend alpha-, gamma-, and delta-tocotrienol; delta- and gamma- forms are generally considered the most bioactive for the senescence-suppressing mechanisms studied in vitro.
Mechanism & clinical data
An early RCT (Mensink et al., AJCN 1999) using 35 mg tocotrienol plus 20 mg tocopherol over 6 weeks in 40 subjects found no lipid benefit. In contrast, a 2025 RCT in chronic kidney disease patients using 300 mg/day TRF for 3 months found reductions in LDL, total cholesterol, and CRP. Mechanistic work (in vitro/preclinical) has proposed that tocotrienols suppress the senescence-associated secretory phenotype (SASP) via NF-kB and mTOR pathway inhibition, a potential senolytic-adjacent mechanism, though this has not been confirmed in human trials. FDA granted GRAS status to tocotrienol-rich preparations in 2010.
Pharmacokinetics
Tocotrienols have a shorter plasma half-life than tocopherols (roughly 4-12 hours depending on isomer), requiring more frequent dosing to maintain circulating levels; trial durations of weeks to months are used to assess clinical endpoints.
Dose & forms
What to watch out for
maj have mild blood-thinning effects at high doses; can interact with anticoagulant/antiplatelet medications; results are inconsistent across trials, so effect on standard cholesterol panels should not be assumed reliable.
Where this dose comes from
The trial dose above is our editorial pick from the published human trials for this ingredient. We choose the dose that the best-available studies used on the endpoint most relevant to longevity. The range shows the lowest and highest doses tested in published trials. The landmark studies below are the papers we read to set it. You can click through and check our work.
When new trials publish, our automated sweeps flag them. If a new study materially changes the dose, we update it through editorial review and record the old dose, new dose, and the triggering study in every affected product's recommendation history. The dose is never changed automatically.
Regelverk status
Timeline
Regelverk events, evidence grade changes, and key research milestones for Tocotrienols, most recent first. Every entry links to its primär source.
-
EU Court sharpens the bar for botanical health claimsA Court of Justice of the European Union ruling in april 2025 further tightened the requirements for how botanical ingredients (herbs, plant extracts) can be marketed with health claims in the EU, effectively removing much of the flexibility of the on-hold list.
-
EU report identifies 117 supplement substances as potential health risksThe HoA Working Group on Food Supplements (26 European countries) published its first report evaluating 117 substances used in food supplements. Of these, 65 were assessed as likely novel foods, 6 were already regulated, 34 had insufficient data, and 12 were prioritized for Article 8 restriction under Regulation (EC) No 1925/2006. The 12 priority substances include ashwagandha, curcumin, melatonin, piperine, St. John's wort, coumarin, p-synephrine, maca, holy basil, Melaleuca, black cohosh, and L-tryptophan. The report drew on 1,500 RASFF alerts reviewed between 2017 and mid-2022.
-
EU Health Claims Regulation adoptedRegulation (EC) No 1924/2006 laid down harmonised rules for nutrition and health claims made on foods, including supplements. Only claims listed in the EU Register of authorised claims can be used. Rejected botanical claims are held in a separate on-hold list.
-
Mensink RP, et al. (1999). A vitamin E concentrate rich in tocotrienols had no effect on serum lipids, lipoproteins, or platelet function in men with mildly elevated serum lipid concentrations. Am J Clin Nutr. PMID 9989682.Mensink RP, et al. (1999). A vitamin E concentrate rich in tocotrienols had no effect on serum lipids, lipoproteins, or platelet function in men with mildly elevated serum lipid concentrations. Am J Clin Nutr. PMID 9989682.
-
EU introduces the Novel Food RegulationRegulation (EC) No 258/97 required any food or food ingredient without a history of consumption in the EU before 15 maj 1997 to be authorised before being placed on the market. This is the framework that captures NMN, spermidine as a supplement ingredient, urolithin A, and many other longevity actives.
Landmark studies
-
Mensink RP, et al. (1999). A vitamin E concentrate rich in tocotrienols had no effect on serum lipids, lipoproteins, or platelet function in men with mildly elevated serum lipid concentrations. Am J Clin Nutr. PMID 9989682.
Mensink RP, et al. (1999). A vitamin E concentrate rich in tocotrienols had no effect on serum lipids, lipoproteins, or platelet function in men with mildly elevated serum lipid concentrations. Am J Clin Nutr. PMID 9989682.
Läs studie →
Found in these produkter
Alla produkter in our catalog that contain Tocotrienols, ranked by our overall score. Ranking is editorial, never paid.
No produkter in our catalog contain this yet.
Buying guides and comparisons
Related ingredients
Se alla in Antioxidant / Senolytic potential →Molekyler in the same class, plus the actives most often formulated alongside Tocotrienols in our catalogue.
Nothing else in the database sits close enough to this molecule to list.
Frequently asked questions
What is Tocotrienols?
Vitamin E exists as eight related molecules — four tocopherols and four tocotrienols. Tocotrienols are found concentrated in palm oil, rice bran oil, and annatto, and have a different, generally more potent antioxidant profile than the common alpha-tocopherol most people know as "vitamin E."
What dose of Tocotrienols should I take?
The trial dose in published human studies is 300 mg per dag, with a range of 50 to 400 mg per dag. Always consult a qualified clinician before starting any supplement.
Is Tocotrienols safe?
maj have mild blood-thinning effects at high doses; can interact with anticoagulant/antiplatelet medications; results are inconsistent across trials, so effect on standard cholesterol panels should not be assumed reliable.
What is the best Tocotrienols supplement?
We track 0 produkter containing Tocotrienols. The top-ranked product scores 0 out of 10 on our composite scale, which evaluates dose, evidence, price, third-party testing, and transparency. See the comparison table above. Scores are editorial judgments, not a scientific standard.
What is the evidence grade for Tocotrienols?
Tocotrienols has evidence grade C, meaning it is backed by mixed or small human trials. Grade A means replicated human RCTs with hard endpoints. Grade B means human RCTs with biomarker outcomes. Grade C means mixed or small human trials. See our evidence grading methodology.
Data verification
Bevisning grades are reviewed when new human RCTs are published. Product counts update automatically as new produkter are added. Dose ranges reflect published trial data, not brand recommendations. Read how we verify.